Multiple Sclerosis

Edit Your Profile

Multiple Sclerosis Journal

publication venue for

Patient and carer perspectives related to research priorities and clinical trials in MOG antibody-associated disease: a survey and focus group study 2025
Rationale and design of a phase III randomised, double-blind, placebo-controlled, multicentre study evaluating the efficacy and safety of treatment with corticoSTeroids at onset, And Rituximab at relapse, of MOG-antibody-associated disease (STAR-MOG) 2025

International Standard Serial Number (ISSN)

1352-4585

Electronic International Standard Serial Number (EISSN)

1477-0970